Literature DB >> 23933582

Differential regulation of cardiac excitation-contraction coupling by cAMP phosphodiesterase subtypes.

Delphine Mika1, Pierre Bobin, Martine Pomérance, Patrick Lechêne, Ruth E Westenbroek, William A Catterall, Grégoire Vandecasteele, Jérôme Leroy, Rodolphe Fischmeister.   

Abstract

AIMS: Multiple phosphodiesterases (PDEs) hydrolyze cAMP in cardiomyocytes, but the functional significance of this diversity is not well understood. Our goal here was to characterize the involvement of three different PDEs (PDE2-4) in cardiac excitation-contraction coupling (ECC). METHODS AND
RESULTS: Sarcomere shortening and Ca(2+) transients were recorded simultaneously in adult rat ventricular myocytes and ECC protein phosphorylation by PKA was determined by western blot analysis. Under basal conditions, selective inhibition of PDE2 or PDE3 induced a small but significant increase in Ca(2+) transients, sarcomere shortening, and troponin I phosphorylation, whereas PDE4 inhibition had no effect. PDE3 inhibition, but not PDE2 or PDE4, increased phospholamban phosphorylation. Inhibition of either PDE2, 3, or 4 increased phosphorylation of the myosin-binding protein C, but neither had an effect on L-type Ca(2+) channel or ryanodine receptor phosphorylation. Dual inhibition of PDE2 and PDE3 or PDE2 and PDE4 further increased ECC compared with individual PDE inhibition, but the most potent combination was obtained when inhibiting simultaneously PDE3 and PDE4. This combination also induced a synergistic induction of ECC protein phosphorylation. Submaximal β-adrenergic receptor stimulation increased ECC, and this effect was potentiated by individual PDE inhibition with the rank order of potency PDE4 = PDE3 > PDE2. Identical results were obtained on ECC protein phosphorylation.
CONCLUSION: Our results demonstrate that PDE2, PDE3, and PDE4 differentially regulate ECC in adult cardiomyocytes. PDE2 and PDE3 play a more prominent role than PDE4 in regulating basal cardiac contraction and Ca(2+) transients. However, PDE4 becomes determinant when cAMP levels are elevated, for instance, upon β-adrenergic stimulation or PDE3 inhibition.

Entities:  

Keywords:  Excitation–contraction coupling; Phosphodiesterase; Protein phosphorylation; cAMP

Mesh:

Substances:

Year:  2013        PMID: 23933582      PMCID: PMC3888219          DOI: 10.1093/cvr/cvt193

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  58 in total

Review 1.  Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family.

Authors:  Y Shakur; L S Holst; T R Landstrom; M Movsesian; E Degerman; V Manganiello
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

2.  Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.

Authors:  H Hidaka; H Hayashi; H Kohri; Y Kimura; T Hosokawa; T Igawa; Y Saitoh
Journal:  J Pharmacol Exp Ther       Date:  1979-10       Impact factor: 4.030

3.  Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.

Authors:  T Sudo; K Tachibana; K Toga; S Tochizawa; Y Inoue; Y Kimura; H Hidaka
Journal:  Biochem Pharmacol       Date:  2000-02-15       Impact factor: 5.858

4.  In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors.

Authors:  T C Rich; T E Tse; J G Rohan; J Schaack; J W Karpen
Journal:  J Gen Physiol       Date:  2001-07       Impact factor: 4.086

5.  Cyclic GMP regulation of the L-type Ca(2+) channel current in human atrial myocytes.

Authors:  G Vandecasteele; I Verde; C Rücker-Martin; P Donzeau-Gouge; R Fischmeister
Journal:  J Physiol       Date:  2001-06-01       Impact factor: 5.182

6.  Beta-adrenergic regulation requires direct anchoring of PKA to cardiac CaV1.2 channels via a leucine zipper interaction with A kinase-anchoring protein 15.

Authors:  Joanne T Hulme; Teddy W-C Lin; Ruth E Westenbroek; Todd Scheuer; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

7.  Modulation of excitation-contraction coupling by isoproterenol in cardiomyocytes with controlled SR Ca2+ load and Ca2+ current trigger.

Authors:  Kenneth S Ginsburg; Donald M Bers
Journal:  J Physiol       Date:  2004-01-14       Impact factor: 5.182

8.  Comparative actions of diazepam and other phosphodiesterase inhibitors on the effects of noradrenaline in rat myocardium.

Authors:  María J Juan-Fita; María L Vargas; Jesús Hernández
Journal:  Pharmacol Toxicol       Date:  2003-07

9.  The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding.

Authors:  Sergio E Martinez; Albert Y Wu; Natalie A Glavas; Xiao-Bo Tang; Stewart Turley; Wim G J Hol; Joseph A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

10.  Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases.

Authors:  Marco Mongillo; Theresa McSorley; Sandrine Evellin; Arvind Sood; Valentina Lissandron; Anna Terrin; Elaine Huston; Annette Hannawacker; Martin J Lohse; Tullio Pozzan; Miles D Houslay; Manuela Zaccolo
Journal:  Circ Res       Date:  2004-06-03       Impact factor: 17.367

View more
  16 in total

1.  Basal Spontaneous Firing of Rabbit Sinoatrial Node Cells Is Regulated by Dual Activation of PDEs (Phosphodiesterases) 3 and 4.

Authors:  Tatiana M Vinogradova; Syevda Sirenko; Yevgeniya O Lukyanenko; Dongmei Yang; Kirill V Tarasov; Alexey E Lyashkov; Nevin J Varghese; Yue Li; Khalid Chakir; Bruce Ziman; Edward G Lakatta
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-06

Review 2.  Cyclic AMP synthesis and hydrolysis in the normal and failing heart.

Authors:  Aziz Guellich; Hind Mehel; Rodolphe Fischmeister
Journal:  Pflugers Arch       Date:  2014-04-24       Impact factor: 3.657

Review 3.  Targeting the sarcomere to correct muscle function.

Authors:  Peter M Hwang; Brian D Sykes
Journal:  Nat Rev Drug Discov       Date:  2015-04-17       Impact factor: 84.694

4.  PDE4B mediates local feedback regulation of β₁-adrenergic cAMP signaling in a sarcolemmal compartment of cardiac myocytes.

Authors:  Delphine Mika; Wito Richter; Ruth E Westenbroek; William A Catterall; Marco Conti
Journal:  J Cell Sci       Date:  2014-01-10       Impact factor: 5.285

5.  AKAP150 participates in calcineurin/NFAT activation during the down-regulation of voltage-gated K(+) currents in ventricular myocytes following myocardial infarction.

Authors:  Madeline Nieves-Cintrón; Dinesh Hirenallur-Shanthappa; Patrick J Nygren; Simon A Hinke; Mark L Dell'Acqua; Lorene K Langeberg; Manuel Navedo; Luis F Santana; John D Scott
Journal:  Cell Signal       Date:  2015-12-24       Impact factor: 4.315

Review 6.  Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.

Authors:  Grace E Kim; David A Kass
Journal:  Handb Exp Pharmacol       Date:  2017

Review 7.  Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.

Authors:  Rima Kamel; Jérôme Leroy; Grégoire Vandecasteele; Rodolphe Fischmeister
Journal:  Nat Rev Cardiol       Date:  2022-09-01       Impact factor: 49.421

8.  Heterologous desensitization of cardiac β-adrenergic signal via hormone-induced βAR/arrestin/PDE4 complexes.

Authors:  Qian Shi; Minghui Li; Delphine Mika; Qin Fu; Sungjin Kim; Jason Phan; Ao Shen; Gregoire Vandecasteele; Yang K Xiang
Journal:  Cardiovasc Res       Date:  2017-05-01       Impact factor: 10.787

9.  Roflumilast and aquaporin-2 regulation in rat renal inner medullary collecting duct.

Authors:  Ezigbobiara N Umejiego; Yanhua Wang; Mark A Knepper; Chung-Lin Chou
Journal:  Physiol Rep       Date:  2017-01

10.  Correlation between endogenous polyamines in human cardiac tissues and clinical parameters in patients with heart failure.

Authors:  Clara Meana; José Manuel Rubín; Carmen Bordallo; Lorena Suárez; Javier Bordallo; Manuel Sánchez
Journal:  J Cell Mol Med       Date:  2015-11-18       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.